Walter Strapps

Chief Scientific Officer at Gemini Therapeutics

Walter Strapps, Ph.D., was most recently Vice President, Discovery Biology at Intellia Therapeutics where he led internal and external CRISPR/Cas9 therapeutic programs through discovery into IND-enabling studies across a range of tissues and indications.

Prior to that he served as Director, RNAi Therapeutics at Merck & Co., Inc. where he led siRNA identification, lead optimization, assay development and management of screening automation and helped Merck to integrate and build up its RNAi Therapeutics group after the acquisition of Sirna Therapeutics in 2006. Prior to that acquisition, he was a scientist at Sirna Therapeutics.

Dr. Strapps earned his B.Sc in biology from McGill University and his Ph.D. in genetics and biology from Columbia University.


  • Chief Scientific Officer

    Current role

  • VP, Gene Therapy